


Accepted Manuscript

Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia:
Current Understanding and Future Directions

S. Bhalla, D. Tremblay, J. Mascarenhas



PII: S2152-2650(16)30117-3

DOI: [10.1016/j.clml.2016.06.012](https://doi.org/10.1016/j.clml.2016.06.012)

Reference: CLML 812

To appear in: *Clinical Lymphoma, Myeloma and Leukemia*

Received Date: 28 March 2016

Revised Date: 11 May 2016

Accepted Date: 1 June 2016

Please cite this article as: Bhalla S, Tremblay D, Mascarenhas J, Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions, *Clinical Lymphoma, Myeloma and Leukemia* (2016), doi: 10.1016/j.clml.2016.06.012.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia:
Current Understanding and Future Directions**

Bhalla S^a, Tremblay D^a, and J Mascarenhas^{b*}

^aDepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY

^bTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

*Corresponding author
John Mascarenhas, MD
Myeloproliferative Disorder Program
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
One Gustave L Levy Place, Box 1079
New York, New York 10029
212 241 3417 telephone
212 876 5276 fax
John.mascarenhas@mssm.edu

Download English Version:

<https://daneshyari.com/en/article/5581749>

Download Persian Version:

<https://daneshyari.com/article/5581749>

[Daneshyari.com](https://daneshyari.com)